HBK Investments’s Starling Oncology Warrant STLNW Stock Holding History

HBK Investments’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$32K	–	854
2021 Q3	$32K	Sell	20,000 -38,599	-66%	-$53.2K	﹤0.01%	700
2021 Q2	$101K	Hold	58,599	–	–	﹤0.01%	737
2021 Q1	$79K	Sell	58,599 -4,900	-8%	-$9.09K	﹤0.01%	766
2020 Q4	$124K	Hold	63,499	–	–	﹤0.01%	668
2020 Q3	$108K	Sell	63,499 -56,461	-47%	-$92.7K	﹤0.01%	608
2020 Q2	$176K	Buy	+119,960	New	+$172K	﹤0.01%	536

Other funds holding STLNW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

USPCM

Union Square Park Capital Management New York $278M AUM 50.01% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

HBK Investments's STLNW Position: Q1 2022 in Review

HBK Investments sold out of Starling Oncology Warrant (STLNW) in Q1 2022, closing a stake of 14,000 shares — an estimated $10K sold.

HBK Investments first reported a position in STLNW in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 12 funds tracked by Wall St. Rank hold STLNW as of Q1 2022.

HBK Investments reported no remaining Starling Oncology Warrant position as of Q1 2022 after selling out during the quarter.
HBK Investments sold 14,000 Starling Oncology Warrant shares in Q1 2022, an estimated $10K.
HBK Investments first reported a position in Starling Oncology Warrant in Q4 2021 and held it in 1 quarter.
HBK Investments's Starling Oncology Warrant position peaked at $10K in Q4 2021.
12 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q1 2022.

Based on HBK Investments's 13F filing for Q1 2022, filed 16 May 2022.